114 related articles for article (PubMed ID: 17414540)
1. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia.
Finger E; Scheinberg M
J Clin Rheumatol; 2007 Apr; 13(2):94-5. PubMed ID: 17414540
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-induced serum sickness in overlapping syndrome between sjögren syndrome and systemic lupus erythematosus.
Ungprasert P; Srivali N; Kittanamongkolchai W; Leeaphorn N; Griger DT
J Clin Rheumatol; 2013 Sep; 19(6):360. PubMed ID: 23965477
[No Abstract] [Full Text] [Related]
3. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
[TBL] [Abstract][Full Text] [Related]
4. Serum sickness following treatment with rituximab.
Todd DJ; Helfgott SM
J Rheumatol; 2007 Feb; 34(2):430-3. PubMed ID: 17295433
[TBL] [Abstract][Full Text] [Related]
5. Serum sickness and severe angioedema following rituximab therapy in RA.
Kumar A; Khamkar K; Gopal H
Int J Rheum Dis; 2012 Feb; 15(1):e6-7. PubMed ID: 22324965
[No Abstract] [Full Text] [Related]
6. Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.
Le Guenno G; Ruivard M; Charra L; Philippe P
Intern Med J; 2011 Feb; 41(2):202-5. PubMed ID: 22747556
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
8. Serum sickness following a first rituximab infusion with no recurrence after the second one.
Mehsen N; Yvon CM; Richez C; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(5):967. PubMed ID: 19032839
[No Abstract] [Full Text] [Related]
9. Serum sickness due to infliximab in a patient with psoriasis.
Krishnan RS; Hsu S
J Drugs Dermatol; 2004; 3(3):305-8. PubMed ID: 15176166
[TBL] [Abstract][Full Text] [Related]
10. Desensitization protocol for rituximab-induced serum sickness.
Fajt ML; Petrov AA
Curr Drug Saf; 2014; 9(3):240-2. PubMed ID: 24861993
[TBL] [Abstract][Full Text] [Related]
11. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
[TBL] [Abstract][Full Text] [Related]
13. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.
Hellerstedt B; Ahmed A
Ann Oncol; 2003 Dec; 14(12):1792. PubMed ID: 14630688
[No Abstract] [Full Text] [Related]
14. Serum sickness-like reaction associated with efalizumab.
Ashraf-Benson S; Wall GC; Veach LA
Ann Pharmacother; 2009 Feb; 43(2):383-6. PubMed ID: 19193578
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-induced serum sickness.
Schutgens RE
Br J Haematol; 2006 Oct; 135(2):147. PubMed ID: 16869826
[No Abstract] [Full Text] [Related]
16. Rituximab-induced serum sickness.
Herishanu Y
Am J Hematol; 2002 Aug; 70(4):329. PubMed ID: 12214584
[No Abstract] [Full Text] [Related]
17. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia.
Catuogno M; Rezai S; Priori R; Magrini L; Valesini G
Rheumatology (Oxford); 2005 Mar; 44(3):406. PubMed ID: 15637037
[No Abstract] [Full Text] [Related]
18. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
[TBL] [Abstract][Full Text] [Related]
20. Severe serum sickness-like syndrome after omalizumab therapy for asthma.
Pilette C; Coppens N; Houssiau FA; Rodenstein DO
J Allergy Clin Immunol; 2007 Oct; 120(4):972-3. PubMed ID: 17716723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
